Malignant: How Bad Policy and Bad Evidence Harm People with Cancer
This is a book about how the actions of human beings—our policies, our standards of evidence, and our drug regulation—incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Dr. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Malignant serves as a great introduction to all the themes when taking a deep dive into clinical oncology trials.
